Patent · US Active

Multi-specific binding proteins for cancer treatment

US11332541B2 · kind B2 · utility

1Cited by

8References

17Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Susanne Hipp · Ingelheim am Rhein, DE
Paul Adam · Wien, AT
Michael Dziegelewski · Newburgh, US
Rajkumar Ganesan · Blue Bell, US
Philip Nicholas Gorman · Prospect, US
Priyanka GUPTA · Danbury, US
Justin Scheer · San Francisco, US
Vladimir H. Voynov · Danbury, US
Pankaj Gupta · Scarsdale, US

Key dates

Filing date	Jun 7, 2019
Grant date	May 17, 2022
Priority date	—
Expiry date	Sep 2, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.